- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07655492
Developing a Tailored Neuropsychological Rehabilitation for Sturge-Weber Syndrome (NPS-SWS)
Exploring the Neuropsychological Profile of Sturge-Weber Syndrome for Developing Tailored Rehabilitation.
The goal of this observational study is to learn about the neuropsychological profile of Sturge-Weber Syndrome (SWS) in children and adults with this rare neurocutaneous condition. SWS affects approximately 1 in 50,000 live births and is characterized by brain blood vessel malformations, facial port-wine stains, and abnormal vascularization in the brain, skin, and eyes. Patients are at high risk for epileptic seizures, stroke-like episodes, glaucoma, and motor and cognitive difficulties. The main questions it aims to answer are:
- What are the specific cognitive strengths and weaknesses in visuospatial abilities, working memory, and executive functions in individuals with SWS?
- What is the detailed neuropsychological profile of patients with SWS who do not have intellectual disability?
- Are there different cognitive-behavioral phenotypes between patients with and without the characteristic facial port-wine stain (PWS)?
- How do clinical variables such as seizure history and brain involvement patterns relate to specific cognitive deficits?
Participants will undergo a comprehensive neuropsychological assessment battery that includes:
- Intellectual functioning tests (K-BIT2) to measure verbal and non-verbal intelligence
- Executive function evaluation (BRIEF2) assessing behavioral regulation, emotional regulation, and cognitive regulation
- Language assessment including receptive vocabulary (PPVT) and grammatical comprehension (TCGB-2)
- Visuospatial skills testing (Beery-Buktenica VMI) evaluating visual-motor integration
- Working memory assessment (WISC-IV/WAIS-IV digit span and spatial span subtests)
- Learning abilities evaluation including reading (Battery for the Assessment of - Developmental Dyslexia and Dysorthography), writing, and mathematical skills (ABCA test)
- Additional assessments for attention, verbal memory, and spatial memory as needed
The study will recruit SWS patients through collaboration with patient associations and Telethon support. Participants will continue their standard medical care throughout the study, and all medications and therapies will be recorded. The neuropsychological testing will be conducted at IRCCS San Raffaele and Sapienza University Department of Psychology.
The study aims to identify a cognitive-behavioral phenotype for SWS, develop evidence-based guidelines for neuropsychological monitoring, create personalized recommendations for educational adaptations, produce training materials for healthcare professionals and educators, and establish a multidisciplinary framework for supporting individuals with SWS. This research addresses a critical knowledge gap, as previous studies have focused mainly on general intellectual functioning and the prevalence of intellectual disability and language disorders, without providing detailed neuropsychological profiles, particularly for patients without intellectual disability.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Laura Piccardi, PhD
- Numéro de téléphone: +39 06 49917527
- E-mail: laura.piccardi@uniroma1.it
Lieux d'étude
-
-
Roma
-
Roma, Roma, Italie, 00185
- Recrutement
- Department of Psychology University of Rome
-
Contact:
- Laura Piccardi, PhD
- Numéro de téléphone: +39 06 49917527
- E-mail: laura.piccardi@uniroma1.it
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Confirmed diagnosis of Sturge-Weber Syndrome (SWS) of any type (Type I, Type II, or Type III) based on clinical and/or neuroimaging findings
- Age 2 years or older at the time of enrollment (children, adolescents, and adults are eligible)
- Ability to cooperate with neuropsychological testing procedures
- Willingness to complete all study assessments within the designated timeframe
Exclusion Criteria:
- Absence of confirmed Sturge-Weber Syndrome (SWS)
- Age younger than 2 years at the time of enrollment
- Inability to cooperate with neuropsychological testing procedures even with accommodations or modifications
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
1. Composite neuropsychological profile across visuospatial, working memory, and executive function domains
Délai: At baseline assessment
|
Assessment of previously uncharacterized cognitive domains in Sturge-Weber Syndrome using three standardized measures administered at baseline: (1) Beery-Buktenica VMI for visuospatial integration; (2) WISC-IV/WAIS-IV Working Memory Index for working memory capacity; (3) BRIEF2 Global Executive Composite for executive functioning. Each measure is scored according to its own normative standard (standard scores Mean=100 SD=15, or T-scores Mean=50 SD=10), then converted to a uniform z-score scale to allow cross-domain comparison and aggregation into a single composite profile score (mean z-score across the three domains). Performance on the composite is classified as impaired (z < -1.5), borderline (z between -1.5 and -1.0), average (z between -1.0 and +1.0), or above average (z > +1.0). Unit of Measure: Mean z-score (composite across three domains) |
At baseline assessment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
2. Composite cognitive, linguistic, and academic functioning profile in Sturge-Weber Syndrome
Délai: At baseline assessment
|
Multidimensional assessment of language, intellectual, and academic functioning using standardized measures administered at baseline. Domains assessed: (1) Language: receptive vocabulary (PPVT) and grammatical comprehension (TCGB-2); (2) General intellectual functioning: K-BIT2 Composite IQ; (3) Academic skills: reading accuracy/speed, writing/spelling accuracy, and mathematical abilities (Battery for Dyslexia/Dysorthographia and ABCA); (4) Supplementary attention and memory when clinically indicated (BVN subtests). All measures are converted to a uniform z-score scale relative to age-based norms and aggregated into a domain-level composite score for each of the four areas above. A global secondary composite (mean z-score across all available domains) summarizes overall functioning. Performance classified as impaired (z < -1.5), borderline (z between -1.5 and -1.0), average, or above average (z > +1.0) per domain. Unit of Measure: Mean z-score (composite across domains) |
At baseline assessment
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Laura Piccardi, PhD, University of Roma La Sapienza
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Infarctus cérébral
- Ischémie cérébrale
- Infarctus
- Nécrose
- Ischémie
- Accident vasculaire cérébral
- Conditions pathologiques, signes et symptômes
- Infarctus du tronc cérébral
Autres numéros d'identification d'étude
- GS25C003
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .